Physician profile
Matthew A Bogoyas
NPI 1336508423
$499,833.92
in general payments reported to CMS, 2019-2025
20 companies · $202K in 2025
The $202K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $213 · 2021: $1,538 · 2022: $27K · 2023: $81K · 2024: $186K · 2025: $202K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $327K · Consulting Fee: $62K · Travel and Lodging: $33K · Honoraria: $29K · Food and Beverage: $19K · Education: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $326,660.25 |
| Consulting Fee | $61,686.50 |
| Travel and Lodging | $32,746.00 |
| Honoraria | $29,200.00 |
| Food and Beverage | $18,649.08 |
| Education | $539.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $155,176.85 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $109,202.67 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $96,021.51 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $70,006.04 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $54,293.42 | 2022-2025 | Auvelity |
| Janssen Scientific Affairs, LLC | $9,143.58 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Janssen Pharmaceuticals, INC | $1,290.98 | 2021-2025 | Invega Sustenna, Invega, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,245.78 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,218.55 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $631.30 | 2021-2025 | Abilify Asimtufii |
| Indivior INC. | $443.91 | 2022-2023 | Perseris, Sublocade |
| Allergan, INC. | $443.22 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $370.19 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $137.35 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $67.45 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $64.37 | 2021 | |
| Abbvie INC. | $35.60 | 2022 | |
| Seqirus USA INC | $15.29 | 2021 | |
| Eisai INC. | $13.98 | 2024 | |
| Vanda Pharmaceuticals INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bogoyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.